Biopharmaceuticals Portfolio In A Biotech Bull Market
Biotech Bull Market 2017 Performance as of 9/5/17
Rayno Biopharmaceutical Portfolio outperforms the market.
XBI was the Best Play up 41.88% YTD.
Biotech stocks broke through the July sector highs as tracked by major ETFs. However we are still about 25% off the July 2015 bubble highs but supported by good earnings fundamentals, strong technicals and potentially a seasonal strong Q4. This leg of the new biotech bull market began in January 2017 after a vicious Q4 2015 sell-off.
- Once again our portfolio model shows that for the average biotech investor one or two ETFs are a good choice.
- The XBI continues to be the leader up over 41% YTD despite greater volatility. We recommended XBI in January at a price of $64.
- Most of our large caps picks did well but the IBB did better up 25.5% YTD.
- Our more speculative small cap picks did extremely well with bluebird bio (BLUE), a CAR-T play, up 103.3% and Foundation Medicine (FMI) an emerging leader in personalized cancer treatment, up 127.4%.
- M&A proved to be a strong driver with the acquisition of Kite Pharma (KITE) by Gilead Sciences (GILD).
Company | Ticker | Date | Price | Price | Perf | 9/5 | Perf % | |
Started | 4/25 | % | P | YTD | ||||
Abbvie | ABBV | 2/3/16 | 56.5 | 65.45 | 16 | 75.25 | 20.12 | |
Amgen | AMGN | 9/12/16 | 172 | 165 | -4 | 176.74 | 20.88 | |
Biogen | BIIB | 2/13/17 | 275 | 286.5 | 4.5 | 315.83 | 11.37 | |
bluebird bio | BLUE | 2/3/16 | 43.75 | 88.1 | 103 | 125.45 | 103.3 | |
Bristol Myers | BMY | 2/16/16 | 61 | 54.2 | -7.7 | 59.81 | 2.36 | |
Foundation Med | FMI | 7/5/16 | 20.4 | 34 | 68 | 40.25 | 127.4 | |
Gilead Sci | GILD | 2/3/16 | 85.8 | 67.3 | -20.9 | 82.56 | 15.29 | |
Roche ADR | RHHBY | 4/4/16 | 30.36 | 32.4 | 7.9 | 31.65 | 10.94 | |
IBB | 6/29/16 | 250 | 296 | 18.4 | 333.04 | 25.5 | ||
XBI | 1/31/17 | 64 | 70.7 | 9.4 | 83.98 | 41.88 | ||
QQQ | n/a | 135.13 | n/a | 144.69 | 22.12 | |||
FBIOX (reference)
|
227.81 | 24.5 |
Disclosure: None.